Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics (FLGT) Q2-25 10-Q highlights
- Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
- Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
- Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
- Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
- Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
- Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
- Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
- Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
- Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
- Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).
Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.
Fulgent Genetics (FLGT) filed a Form 4 showing that CFO & Treasurer Paul Kim had 2,743 common shares withheld on 07/26/2025 to cover taxes upon the vesting of RSUs tied to the 2022 Fulgent Pharma merger. The transaction was coded “F,” meaning it was an automatic, non-discretionary share surrender for tax withholding, not an open-market sale. The shares were valued at an implied $18.37 each (company-supplied price).
After the withholding, Kim directly owns 339,828 shares, so his economic exposure fell by <1 %. No derivative securities were exercised or disposed of, and no cash changed hands. Because the disposition is routine and immaterial relative to Kim’s total stake, the filing is largely neutral for investors and does not alter the company’s fundamental outlook.